Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Passage Bio (NASDAQ: PASG) is a clinical-stage genetic medicines company on a mission to develop and commercialize transformative therapies for patients suffering from devastating rare monogenic central nervous system (CNS) disorders. The company leverages a strategic collaboration and licensing agreement with the University of Pennsylvania's Gene Therapy Program (GTP), a leader in gene therapy research and development, to access a broad portfolio of AAV-delivered gene therapies and cutting-edge vector engineering and manufacturing capabilities. Their pipeline focuses on conditions with significant unmet medical needs, including GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia (FTD).
Serves as the primary corporate office, housing executive leadership, clinical development, regulatory affairs, research and development oversight, and administrative functions.
Located in a prominent commercial skyscraper in Center City Philadelphia, offering modern office facilities and convenient access to the city's biotech ecosystem.
Likely a dynamic, science-driven, and collaborative environment, focused on innovation and achieving milestones in the development of life-changing therapies for rare diseases. Emphasis on patient-centricity and scientific rigor.
The Philadelphia location is strategic, placing Passage Bio within a vibrant hub for life sciences and in close proximity to key academic partners like the University of Pennsylvania. This facilitates collaboration and talent acquisition.
Passage Bio's primary operations are centered in the United States. Their global reach is mainly through clinical trial sites, which may be located in various countries to ensure diverse patient enrollment for their rare disease programs. They also engage with the international scientific and medical community for research collaborations and to stay at the forefront of gene therapy advancements.
One Commerce Square, 2005 Market Street, Suite 1050
Philadelphia
PA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Passage Bio' leadership includes:
Passage Bio has been backed by several prominent investors over the years, including:
Passage Bio has seen significant leadership renewal in the past year, with new appointments to key C-suite positions including CEO, CFO, and CMO, to guide its clinical and strategic objectives.
Discover the tools Passage Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Passage Bio likely uses common corporate email formats. The most prevalent patterns for companies of this nature are [first_initial][last]@passagebio.com or [first].[last]@passagebio.com. For example, Jane Doe might be jdoe@passagebio.com or jane.doe@passagebio.com.
[first_initial][last]@passagebio.com
Format
wchoi@passagebio.com
Example
70%
Success rate
GlobeNewswire • January 9, 2024
Passage Bio announced the appointments of Simona King as Chief Financial Officer and Mark Forman, M.D., Ph.D., as Chief Medical Officer. These appointments aim to strengthen the company's leadership team as it advances its pipeline of genetic medicines for CNS disorders....more
GlobeNewswire • August 1, 2023
Passage Bio announced the appointment of William Chou, M.D., as its new President and Chief Executive Officer, and a member of the Board of Directors. Dr. Chou brings extensive experience in clinical development, particularly in rare diseases and gene therapy....more
GlobeNewswire • May 8, 2024
Passage Bio provided an update on its clinical programs, including its lead program for GM1 gangliosidosis, and reported financial results for the first quarter of 2024. The company highlighted progress in trial enrollment and outlined upcoming milestones....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Passage Bio, are just a search away.